title: Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy.
abstract: BACKGROUND
  Brain natriuretic peptide (BNP) correlates well with left ventricular wall hypertrophy and the severity of left ventricular outflow tract (LVOT) obstruction in patients with hypertrophic cardiomyopathy (HCM). The purpose of this study was to investigate the correlation of BNP levels with clinical status and left ventricular function in HCM patients.
  
  
  METHODS
  In 32 patients with HCM (age 58 +/- 14 years) we evaluated: (a) the severity of dyspnea and angina; (b) BNP plasma levels; (c) left ventricular wall thickness, sphericity index and mitral regurgitation; (d) LVOT obstruction; (e) ejection fraction; (f) left ventricular diastolic function, global and regional, by tissue Doppler imaging.
  
  
  RESULTS
  BNP plasma levels correlated positively with dyspnea (r = 0.460, p < 0.001), angina (r = 0.460, p = 0.008), mitral regurgitation (r = 0.600, p < 0.001), thickness of interventricular septum (r = 0.526, p = 0.002), and LVOT obstruction (r = 0.551, p = 0.001 and r = 0.603, p < 0.001 for latent obstruction), while they were negatively correlated with left ventricular sphericity index (r = -0.368, p = 0.038). BNP plasma levels were strongly correlated with E/Vp and E/Eal (Vp: flow propagation velocity, Eal: E on the lateral side of the mitral annulus), representing the left ventricular filling pressures, and with some other parameters of regional diastolic function: Ams (A at the mid-segment of the interventricular septum) r = -0.518, p = 0.002; Aas (A on the septal side of the mitral annulus) r = -0.454, p = 0.009; Aal (A on the lateral side of the mitral annulus) r = -0.467, p = 0.007. From multiple regression analysis, angina and the ratio E/Eal were the strongest predictors of BNP plasma levels.
  
  
  CONCLUSIONS
  BNP plasma levels in HCM patients can be used as an adjunctive objective method of evaluating cardiac dysfunction through their correlation with angina and left ventricular filling pressures.
authors.affiliation: Cardiology Department of Athens General Hospital G. Genimatas, Athens, Greece.
authors.forename: Fotis K
authors.initials: FK
authors.lastname: Panou
authors.forename: Vasiliki K
authors.initials: VK
authors.lastname: Kotseroglou
authors.forename: John A
authors.initials: JA
authors.lastname: Lakoumentas
authors.forename: Stavroula A
authors.initials: SA
authors.lastname: Chrysanthopoulou
authors.forename: John A
authors.initials: JA
authors.lastname: Armeniakos
authors.forename: Theodora
authors.initials: T
authors.lastname: Stratigou
authors.forename: Helen
authors.initials: H
authors.lastname: Veve
authors.forename: Apostolos A
authors.initials: AA
authors.lastname: Zacharoulis
mesh_terms: D000328:Adult; D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000097:blood* / Q000000981:diagnostic imaging / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000175:diagnosis / Q000503:physiopathology; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D012044:Regression Analysis; D012680:Sensitivity and Specificity; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis* / Q000503:physiopathology
chemical_list: D020097:Natriuretic Peptide, Brain